Table 6. Sensitivity and specificity tests of CA19-9 and RNLS levels to predict resection in patients with locally advanced/borderline resectable pancreatic adenocarcinoma.

	Sensitivity (95% CI)	Specificity (95% CI)
RNLS (Median)	43.10% (20.16%-56.77%)	27.78% (9.69%-53.48%)
RNLS (AUC)	70.69% (57.27%-81.91%)	66.67% (40.99%-86.66%)
CA19-9	0.00% (0.00%-45.93%)	50.00% (24.65%-75.35%)